Physician profile
Will W Lee
NPI 1982694600
$4,536.38
in general payments reported to CMS, 2019-2025
24 companies · $22.06 in 2025
The $22.06 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $210 · 2021: $291 · 2022: $2,110 · 2023: $222 · 2024: $231 · 2025: $22.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $1,073.34 | 2022 | |
| Abbvie INC. | $862.94 | 2019-2021 | |
| Dr.Reddy'S Laboratories,INC. | $783.00 | 2022 | |
| Exeltis, USA INC. | $297.42 | 2020-2024 | Slynd |
| Duchesnay USA Incorporated | $287.78 | 2019 | |
| Evofem Biosciences, INC. | $224.39 | 2021-2024 | Phexxi |
| Roche Diagnostics Corporation | $189.35 | 2019-2020 | |
| Coopersurgical, INC. | $150.94 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $136.47 | 2022-2025 | |
| Shield Therapeutics INC | $94.36 | 2023-2024 | Accrufer |
| Millicent US INC | $69.72 | 2020 | |
| Agile Therapeutics, INC. | $67.36 | 2021-2023 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $36.25 | 2019-2020 | |
| Lupin INC. | $35.00 | 2020 | |
| Merck Sharp & Dohme LLC | $33.74 | 2019-2024 | Gardasil 9, Gardasil |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $27.64 | 2019 | |
| Biogen, INC. | $26.22 | 2024 | Zurzuvae |
| Avion Pharmaceuticals | $25.43 | 2022 | |
| Medtronic, INC. | $25.00 | 2021 | |
| Astellas Pharma US INC | $23.07 | 2023 | Veozah |
| Myovant Sciences INC. | $18.99 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $18.29 | 2024 | Vivjoa |
| Vertical Pharmaceuticals, LLC | $15.90 | 2019 | |
| Hologic Sales and Service, LLC | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Will Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.